More: 2008 Gastrointestinal Cancers Symposium (GCS)

New Therapeutic Approaches for Patients With Stage III Colorectal Cancer CME

January 25 - 27, 2008, Orlando, Florida

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the 2008 Gastrointestinal Cancers Symposium.

Release Date: February 27, 2008; Valid for credit through February 27, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 2008 Gastrointestinal Cancers Symposium. These materials and the related activity are not sanctioned by the 2008 Gastrointestinal Cancers Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Roche
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review current standard regimens for adjuvant treatment of patients with Stage III colorectal cancer
  2. Report and assess data from clinical trials of adjuvant treatment regimens for patients with Stage III colorectal cancer
  3. Explain new methods in development for identifying patients most likely to benefit from adjuvant chemotherapy (eg, molecular characterization)
  4. Discuss special considerations in the adjuvant treatment setting, including convenience, toxicities, and adherence, that might be taken into account when selecting therapeutic regimens
  5. Describe future directions, both with respect to new drugs and/or modalities and new strategies (eg, shorter dosing schedules, integrating biologics)
Authors and Disclosures

Edward Chu, MD
Disclosure: Edward Chu, MD, has disclosed that he has served as an advisor or consultant to Bristol-Myers Squibb/ImClone, Pfizer, and Roche.


John L. Marshall, MD
Disclosure: John L. Marshall, MD, has disclosed that he has received grants for clinical research and educational activities and has served as an advisor or consultant to Amgen, Bristol-Myers Squibb, Genentech, Roche, and sanofi-aventis.


Michael J. O'Connell, MD
Disclosure: Michael J. O'Connell, MD, has disclosed that he has served as an advisor or consultant to Genomic Health, ImClone, and sanofi-aventis.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.